Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=8 Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
Interaction Drug Food
Primary: Midazolam Area Under the Concentration vs. Time Curve (AUC) — 58.3; 80.8 nM * hr
N/A N=348 Emergency Department (ED) Drug Interaction in Emergency Department Patients
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Phase 4 N=28 Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin
Healthy
Primary: NK-104 AUC — 208.92 ng * h/mL
N/A N=125 Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
Pulmonary Arterial Hypertension
Primary: Characterisation of Medication Levels — 5.54; 2.18; 1.81; 1.53 MOM
Phase 1 N=16 Drug Drug Interaction of BI 201335 and Tenofovir
HIV Infections
Primary: Steady-state Pharmacokinetics of AUC0-24 of Tenofovir on Day 7 and on Day 15 — 2700; 3290 ng*h/mL
Phase 1 N=29 Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
Phase 1 N=30 Transporter Cocktail Mutual Interaction
Healthy
Primary: Area Under the Curve of Digoxin From 0 to Last Quantifiable Data Point (AUC 0-tz) — 11.549; 11.981 nanomole hour per liter (nmol·h/L)
N/A N=10 The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
Phase 4 N=10 Drug-Drug Interaction Between Rifampin and Fluvastatin
Drug-drug Interaction
Primary: AUC — 242; 642; 124; 371 ng/mL·h
N/A N=25 Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
HIV · Hepatitis C
Primary: Simeprevir AUC Pharmacokinetics — 30946; 30333 ng*h/mL
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL
Phase 1 N=11 Doravirine, Rifapentine and Isoniazid Interaction
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
Phase 4 N=28 Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin
Healthy
Primary: NK-104 AUC — 192.00 ng * h/mL
Phase 4 N=24 Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
Healthy Volunteers
Primary: Area Under the Curve From Time 0 to Tau (AUC 0-τ) — 113.92 ng•h/mL
Phase 4 N=30 Drug Interaction Study of Colchicine and Theophylline
Healthy
Primary: Time to Reach the Maximum Plasma Concentration (Tmax) of Theophylline — 1.25; 1.5 hours — p=0.5663
Phase 1 N=27 Drug-Drug Interaction Study: ASP2151 and Midazolam
Healthy
Primary: Peak Plasma Concentration (Cmax) of Midazolam — 34.5; 23.4; 38.8; 36.8 ng/mL
Early Phase 1 N=22 Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Interaction, Adverse Herb-Drug · Diabetes Mellitus, Type 2
Primary: Metformin AUC — 59.6; 54.5; 57.3 mcg*hr/mL
Phase 4 N=8 Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients
Kidney Transplantation
Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006
Phase 1 N=24 Drug-Drug Interaction Between Colchicine and Verapamil ER
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2,968.42; 3,850.63 pg/mL
Phase 1 N=18 Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin
Healthy
Primary: Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 5571.70; 5685.69 nmol*h/L
Phase 4 N=7 Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Multidrug-resistant Tuberculosis · Extensively Drug-resistant Tuberculosis
Primary: Area Under the Time Concentration Curve (AUC0-12h) of Linezolid in Plasma After Addition of 0mg, 250mg, or 500mg Clarithromycin (CLA). — 36.3; 61.0; 67.2 mg*h/L
Phase 1 N=16 DDI Between BI Empagliflozin (10773) and Verapamil
Healthy
Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5190; 5340 nmol*h/L
N/A N=19 Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction
HIV
Primary: AUC — 94.17; 34.67; 100.44; 32.58 h*microgram/mL
Phase 1 N=24 Drug-Drug Interaction Between Colchicine and Ritonavir
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 1,869.50; 4,993.06 pg/mL
N/A N=26 Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
Hepatitis C · HIV
Primary: Boceprevir AUC Pharmacokinetics — 4601 ng*hr/mL
Phase 1 N=30 Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Healthy
Primary: Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole — 217686; 215809 ng*h/ml
Phase 1 N=24 Drug-Drug Interaction Study of Colchicine and Clarithromycin
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 2.84; 8.44 ng/mL
Phase 1 N=30 Drug-Drug Interaction Study of Colchicine and Theophylline
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 9.76; 9.79 µg/mL
Phase 1 N=24 Drug - Drug Interaction Study of Quinine Sulfate and Ciprofloxacin
Healthy
Primary: Maximum Plasma Concentration(Cmax) — 4,240.65; 4,521.20 ng/mL